{"id":870395,"date":"2025-08-04T19:20:14","date_gmt":"2025-08-04T23:20:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ufp-technologies-announces-record-q2-results\/"},"modified":"2025-08-04T19:20:14","modified_gmt":"2025-08-04T23:20:14","slug":"ufp-technologies-announces-record-q2-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ufp-technologies-announces-record-q2-results\/","title":{"rendered":"UFP Technologies Announces Record Q2 Results"},"content":{"rendered":"
\n

NEWBURYPORT, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) — UFP Technologies, Inc.<\/a> (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $17.2 million or $2.21 per diluted common share outstanding for its second quarter ended June\u00a030, 2025, compared to net income of $13.6 million or $1.75 per diluted common share outstanding for the same quarter in 2024. Adjusted earnings per diluted common share outstanding grew 27% to $2.50. Sales for the second quarter were $151.2 million compared to sales of $110.2\u00a0million in the second quarter of 2024. Net income for the six-month period ended June 30, 2025, was $34.4 million or $4.42 per diluted common share outstanding compared to net income of $26.2 million or $3.38 per diluted common share outstanding for the same period in 2024. Sales for the six-month period ended June 30, 2025, were $299.3 million compared to sales of $215.2\u00a0million for the same period in 2024. Throughout this news release, reference is made to non-GAAP measures including organic sales growth, adjusted operating income, adjusted SG&A, adjusted net income and EPS, and EBITDA and adjusted EBITDA. Please see \u201cNon-GAAP Financial Information\u201d at the end of this news release.<\/p>\n

\u201cI am very pleased with our Q2 results,\u201d said R. Jeffrey Bailly, Chairman & CEO. \u201cSales grew 37%, driven by strong contributions from our 2024 acquisitions combined with 5% organic growth. Our MedTech business grew 46% while our Advanced Components business declined 20%. Adjusted operating income and adjusted net income grew 35% and 27%, respectively. Gross margins were 28.8% despite being impacted by approximately $1.2 million in incremental labor costs at our AJR facility. This was due to recent turnover in the workforce related to our post-acquisition review of US employment eligibility through E-Verify protocols. We have successfully recruited legally eligible replacement associates and anticipate that Q3 will be the low point of labor inefficiencies, with gradual improvement beginning in the fourth quarter.\u201d<\/p>\n

\u201cWe completed two acquisitions during our second quarter: Universal Plastics & Engineering (UNIPEC) and Techno Plastics Industries (TPI),\u201d said Bailly. These will expand our capabilities in tight-tolerance specialty film components and in thermoplastic molding for the medical device market. In addition, we continued to make progress with our expansion plans in Santiago and La Romana, Dominican Republic, to accommodate further anticipated growth in the safe patient handling and robotic-assisted surgery markets.\u201d<\/p>\n

\u201cOur pipeline of new growth opportunities\u2014both internal and via acquisition\u2014is strong and growing,\u201d Bailly said. \u201cFor these reasons and more, we remain excited about our future.\u201d<\/p>\n

\n Financial Highlights for Q<\/u>
\n 2 and YTD<\/u>
\n 202<\/u>
\n 5<\/u>\n <\/p>\n